Antimicrobial susceptibility of Clostridioides difficile.An Argentinian multicenter study of isolates fromhuman patients
- Autores
- Rollet, Raquel; Vaustat, Daniela; Laube, Gerardo
- Año de publicación
- 2025
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión publicada
- Descripción
- Fil: Clostridioides difficile is an etiological agent of diarrhea, and the use of antibiotics is one of the main risk factors for infection. Antimicrobials used for treatment are vancomycin (VAN), metronidazole (MET), and fidaxomicin. Resistant strains have been detected, exhibiting regional and institutional differences. The aim of this work was to determine the susceptibility profile of C. difficile clinical isolates to 14 antimicrobials, and to compare resistance among participating centers. A total of 208 consecutive isolates recovered from seven Argentinian hospitals between January 2018 and March 2020 were studied. MIC was determined by the agar dilution method (CLSI-M100 29ED). Azithromycin (AZM), clindamycin (CLI), ertapenem (ETP), imipenem (IMI), levofloxacin (LEV), linezolid (LNZ), meropenem (MER), metronidazole (MET),moxifloxacin (MOX), piperacillin---tazobactam (PTZ), rifaximin (RFX), teicoplanin (TEI), tigecy-cline (TGC), and VAN, were tested. The results were analyzed with SPSS 21.0. Chi-square wasused to compare data, and statistical significance was set at p < 0.05. Susceptibility percentageswere as follows: VAN, TEI, and MET, 100%; TGC, 97.6%; PTZ, 96.2%; LNZ, 95.2%; MER, 99.5%; ETP,60.9%; IMI, 42.8%; RFX, 55.6%; LEV, 48.6%; MOX, 46.1%; CLI, 29.9%; and azithromycin, 17.8%.Significant differences in resistance among centers were observed for: RFX (16.7%---91.7%), CLI(41.2%---86.1%), MOX (22.9%---97.2%), IMI (0%---55.6%), and azithromycin (62.5%---97.2%). Multidrugresistance (MDR) was detected in 80 isolates (38.5%), of which 63 (78.7%) were resistant to threefamilies of antimicrobial agents and 17 (21.3%) were resistant to four. The most frequent combi-nations were RFX---MOX---CLI, present in 48 (60.0%) isolates, and RFX---IMI---MOX---CLI in 17 (21.3%)isolates. VAN, TEI, and MET were the most active antimicrobials in vitro against C. difficilestrains. MER was the most active carbapenem, whereas IMI was the least active. We highlightthe differences across institutions that could reflect epidemiological characteristics, and/orthe dissemination of clones in each institution.
Fil: Rollet, Raquel. Instituto Universitario de Ciencias de la Salud. Fundación Barceló; Argentina.
Fil: Vaustat, Daniela. Instituto Universitario de Ciencias de la Salud. Fundación Barceló; Argentina.
Fil: Laube, Gerardo. Instituto Universitario de Ciencias de la Salud. Fundación Barceló; Argentina. - Materia
-
ARTICULO
MICROBIOLOGIA
CLOSTRIDIOIDES DIFFICILE
ANTIBIOTICOS - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- Repositorio
.jpg)
- Institución
- Fundación H. A. Barceló
- OAI Identificador
- oai:repositorio.barcelo.edu.ar:123456789/1120
Ver los metadatos del registro completo
| id |
RIBARCELO_50703762c63fd69a0699b330a855e593 |
|---|---|
| oai_identifier_str |
oai:repositorio.barcelo.edu.ar:123456789/1120 |
| network_acronym_str |
RIBARCELO |
| repository_id_str |
a |
| network_name_str |
Repositorio Institucional (Fundacion Barceló) |
| spelling |
Antimicrobial susceptibility of Clostridioides difficile.An Argentinian multicenter study of isolates fromhuman patientsRollet, RaquelVaustat, DanielaLaube, GerardoARTICULOMICROBIOLOGIACLOSTRIDIOIDES DIFFICILEANTIBIOTICOSFil: Clostridioides difficile is an etiological agent of diarrhea, and the use of antibiotics is one of the main risk factors for infection. Antimicrobials used for treatment are vancomycin (VAN), metronidazole (MET), and fidaxomicin. Resistant strains have been detected, exhibiting regional and institutional differences. The aim of this work was to determine the susceptibility profile of C. difficile clinical isolates to 14 antimicrobials, and to compare resistance among participating centers. A total of 208 consecutive isolates recovered from seven Argentinian hospitals between January 2018 and March 2020 were studied. MIC was determined by the agar dilution method (CLSI-M100 29ED). Azithromycin (AZM), clindamycin (CLI), ertapenem (ETP), imipenem (IMI), levofloxacin (LEV), linezolid (LNZ), meropenem (MER), metronidazole (MET),moxifloxacin (MOX), piperacillin---tazobactam (PTZ), rifaximin (RFX), teicoplanin (TEI), tigecy-cline (TGC), and VAN, were tested. The results were analyzed with SPSS 21.0. Chi-square wasused to compare data, and statistical significance was set at p < 0.05. Susceptibility percentageswere as follows: VAN, TEI, and MET, 100%; TGC, 97.6%; PTZ, 96.2%; LNZ, 95.2%; MER, 99.5%; ETP,60.9%; IMI, 42.8%; RFX, 55.6%; LEV, 48.6%; MOX, 46.1%; CLI, 29.9%; and azithromycin, 17.8%.Significant differences in resistance among centers were observed for: RFX (16.7%---91.7%), CLI(41.2%---86.1%), MOX (22.9%---97.2%), IMI (0%---55.6%), and azithromycin (62.5%---97.2%). Multidrugresistance (MDR) was detected in 80 isolates (38.5%), of which 63 (78.7%) were resistant to threefamilies of antimicrobial agents and 17 (21.3%) were resistant to four. The most frequent combi-nations were RFX---MOX---CLI, present in 48 (60.0%) isolates, and RFX---IMI---MOX---CLI in 17 (21.3%)isolates. VAN, TEI, and MET were the most active antimicrobials in vitro against C. difficilestrains. MER was the most active carbapenem, whereas IMI was the least active. We highlightthe differences across institutions that could reflect epidemiological characteristics, and/orthe dissemination of clones in each institution.Fil: Rollet, Raquel. Instituto Universitario de Ciencias de la Salud. Fundación Barceló; Argentina.Fil: Vaustat, Daniela. Instituto Universitario de Ciencias de la Salud. Fundación Barceló; Argentina.Fil: Laube, Gerardo. Instituto Universitario de Ciencias de la Salud. Fundación Barceló; Argentina.Instituto Universitario de Ciencias de la Salud – Fundación BarcelóLitterio, MirtaCastello, LilianaFernández-Canigia, LilianaBarberis, ClaudiaLegaria, María CristinaAzula, NataliaMaldonado, María LauraPredari, Silvia CarlaRossettih, María Adelaida2025-09-172025-11-19T19:52:27Zinfo:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfhttps://repositorio.barcelo.edu.ar/handle/123456789/1120enginfo:eu-repo/semantics/openAccessreponame:Repositorio Institucional (Fundacion Barceló)instname:Fundación H. A. Barceló2026-04-24T11:45:20Zoai:repositorio.barcelo.edu.ar:123456789/1120instacron:BARCELOInstitucionalhttp://repositorio.barcelo.edu.ar/greenstone/cgi-bin/library.cgiUniversidad privadaNo correspondehttp://repositorio.barcelo.edu.ar/greenstone/cgi-bin/oaiserver.cgilrodriguezares@barcelo.edu.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:a2026-04-24 11:45:20.932Repositorio Institucional (Fundacion Barceló) - Fundación H. A. Barcelófalse |
| dc.title.none.fl_str_mv |
Antimicrobial susceptibility of Clostridioides difficile.An Argentinian multicenter study of isolates fromhuman patients |
| title |
Antimicrobial susceptibility of Clostridioides difficile.An Argentinian multicenter study of isolates fromhuman patients |
| spellingShingle |
Antimicrobial susceptibility of Clostridioides difficile.An Argentinian multicenter study of isolates fromhuman patients Rollet, Raquel ARTICULO MICROBIOLOGIA CLOSTRIDIOIDES DIFFICILE ANTIBIOTICOS |
| title_short |
Antimicrobial susceptibility of Clostridioides difficile.An Argentinian multicenter study of isolates fromhuman patients |
| title_full |
Antimicrobial susceptibility of Clostridioides difficile.An Argentinian multicenter study of isolates fromhuman patients |
| title_fullStr |
Antimicrobial susceptibility of Clostridioides difficile.An Argentinian multicenter study of isolates fromhuman patients |
| title_full_unstemmed |
Antimicrobial susceptibility of Clostridioides difficile.An Argentinian multicenter study of isolates fromhuman patients |
| title_sort |
Antimicrobial susceptibility of Clostridioides difficile.An Argentinian multicenter study of isolates fromhuman patients |
| dc.creator.none.fl_str_mv |
Rollet, Raquel Vaustat, Daniela Laube, Gerardo |
| author |
Rollet, Raquel |
| author_facet |
Rollet, Raquel Vaustat, Daniela Laube, Gerardo |
| author_role |
author |
| author2 |
Vaustat, Daniela Laube, Gerardo |
| author2_role |
author author |
| dc.contributor.none.fl_str_mv |
Litterio, Mirta Castello, Liliana Fernández-Canigia, Liliana Barberis, Claudia Legaria, María Cristina Azula, Natalia Maldonado, María Laura Predari, Silvia Carla Rossettih, María Adelaida |
| dc.subject.none.fl_str_mv |
ARTICULO MICROBIOLOGIA CLOSTRIDIOIDES DIFFICILE ANTIBIOTICOS |
| topic |
ARTICULO MICROBIOLOGIA CLOSTRIDIOIDES DIFFICILE ANTIBIOTICOS |
| dc.description.none.fl_txt_mv |
Fil: Clostridioides difficile is an etiological agent of diarrhea, and the use of antibiotics is one of the main risk factors for infection. Antimicrobials used for treatment are vancomycin (VAN), metronidazole (MET), and fidaxomicin. Resistant strains have been detected, exhibiting regional and institutional differences. The aim of this work was to determine the susceptibility profile of C. difficile clinical isolates to 14 antimicrobials, and to compare resistance among participating centers. A total of 208 consecutive isolates recovered from seven Argentinian hospitals between January 2018 and March 2020 were studied. MIC was determined by the agar dilution method (CLSI-M100 29ED). Azithromycin (AZM), clindamycin (CLI), ertapenem (ETP), imipenem (IMI), levofloxacin (LEV), linezolid (LNZ), meropenem (MER), metronidazole (MET),moxifloxacin (MOX), piperacillin---tazobactam (PTZ), rifaximin (RFX), teicoplanin (TEI), tigecy-cline (TGC), and VAN, were tested. The results were analyzed with SPSS 21.0. Chi-square wasused to compare data, and statistical significance was set at p < 0.05. Susceptibility percentageswere as follows: VAN, TEI, and MET, 100%; TGC, 97.6%; PTZ, 96.2%; LNZ, 95.2%; MER, 99.5%; ETP,60.9%; IMI, 42.8%; RFX, 55.6%; LEV, 48.6%; MOX, 46.1%; CLI, 29.9%; and azithromycin, 17.8%.Significant differences in resistance among centers were observed for: RFX (16.7%---91.7%), CLI(41.2%---86.1%), MOX (22.9%---97.2%), IMI (0%---55.6%), and azithromycin (62.5%---97.2%). Multidrugresistance (MDR) was detected in 80 isolates (38.5%), of which 63 (78.7%) were resistant to threefamilies of antimicrobial agents and 17 (21.3%) were resistant to four. The most frequent combi-nations were RFX---MOX---CLI, present in 48 (60.0%) isolates, and RFX---IMI---MOX---CLI in 17 (21.3%)isolates. VAN, TEI, and MET were the most active antimicrobials in vitro against C. difficilestrains. MER was the most active carbapenem, whereas IMI was the least active. We highlightthe differences across institutions that could reflect epidemiological characteristics, and/orthe dissemination of clones in each institution. Fil: Rollet, Raquel. Instituto Universitario de Ciencias de la Salud. Fundación Barceló; Argentina. Fil: Vaustat, Daniela. Instituto Universitario de Ciencias de la Salud. Fundación Barceló; Argentina. Fil: Laube, Gerardo. Instituto Universitario de Ciencias de la Salud. Fundación Barceló; Argentina. |
| description |
Fil: Clostridioides difficile is an etiological agent of diarrhea, and the use of antibiotics is one of the main risk factors for infection. Antimicrobials used for treatment are vancomycin (VAN), metronidazole (MET), and fidaxomicin. Resistant strains have been detected, exhibiting regional and institutional differences. The aim of this work was to determine the susceptibility profile of C. difficile clinical isolates to 14 antimicrobials, and to compare resistance among participating centers. A total of 208 consecutive isolates recovered from seven Argentinian hospitals between January 2018 and March 2020 were studied. MIC was determined by the agar dilution method (CLSI-M100 29ED). Azithromycin (AZM), clindamycin (CLI), ertapenem (ETP), imipenem (IMI), levofloxacin (LEV), linezolid (LNZ), meropenem (MER), metronidazole (MET),moxifloxacin (MOX), piperacillin---tazobactam (PTZ), rifaximin (RFX), teicoplanin (TEI), tigecy-cline (TGC), and VAN, were tested. The results were analyzed with SPSS 21.0. Chi-square wasused to compare data, and statistical significance was set at p < 0.05. Susceptibility percentageswere as follows: VAN, TEI, and MET, 100%; TGC, 97.6%; PTZ, 96.2%; LNZ, 95.2%; MER, 99.5%; ETP,60.9%; IMI, 42.8%; RFX, 55.6%; LEV, 48.6%; MOX, 46.1%; CLI, 29.9%; and azithromycin, 17.8%.Significant differences in resistance among centers were observed for: RFX (16.7%---91.7%), CLI(41.2%---86.1%), MOX (22.9%---97.2%), IMI (0%---55.6%), and azithromycin (62.5%---97.2%). Multidrugresistance (MDR) was detected in 80 isolates (38.5%), of which 63 (78.7%) were resistant to threefamilies of antimicrobial agents and 17 (21.3%) were resistant to four. The most frequent combi-nations were RFX---MOX---CLI, present in 48 (60.0%) isolates, and RFX---IMI---MOX---CLI in 17 (21.3%)isolates. VAN, TEI, and MET were the most active antimicrobials in vitro against C. difficilestrains. MER was the most active carbapenem, whereas IMI was the least active. We highlightthe differences across institutions that could reflect epidemiological characteristics, and/orthe dissemination of clones in each institution. |
| publishDate |
2025 |
| dc.date.none.fl_str_mv |
2025-09-17 2025-11-19T19:52:27Z |
| dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.none.fl_str_mv |
https://repositorio.barcelo.edu.ar/handle/123456789/1120 |
| url |
https://repositorio.barcelo.edu.ar/handle/123456789/1120 |
| dc.language.none.fl_str_mv |
eng |
| language |
eng |
| dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess |
| eu_rights_str_mv |
openAccess |
| dc.format.none.fl_str_mv |
application/pdf |
| dc.publisher.none.fl_str_mv |
Instituto Universitario de Ciencias de la Salud – Fundación Barceló |
| publisher.none.fl_str_mv |
Instituto Universitario de Ciencias de la Salud – Fundación Barceló |
| dc.source.none.fl_str_mv |
reponame:Repositorio Institucional (Fundacion Barceló) instname:Fundación H. A. Barceló |
| reponame_str |
Repositorio Institucional (Fundacion Barceló) |
| collection |
Repositorio Institucional (Fundacion Barceló) |
| instname_str |
Fundación H. A. Barceló |
| repository.name.fl_str_mv |
Repositorio Institucional (Fundacion Barceló) - Fundación H. A. Barceló |
| repository.mail.fl_str_mv |
lrodriguezares@barcelo.edu.ar |
| _version_ |
1863375299753803776 |
| score |
13.05261 |